CoChat

Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer

Liu, Xu, Lu, Ying, Xu, Yunchao, Hou, Sizhu, Huang, Jinli, Wang, Bo, Zhao, Jinyao, Xia, Shilin, Fan, Shujun, Yu, Xiaotang, Du, Yue, Hou, Li, Li, Zhiyue, Ding, Zijie, An, Shuo, Huang, Bo, Li, Lianhong, Tang, Jianwu, Ju, Jingfang, Guan, Hongwei, Song, Bo · 2019 · Cancer Letters
Cited by 113

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Exosomal transfer of oncogenic miRNAs can enhance recipient cell growth, metastasis and chemoresistance. Currently we found that microRNA-501-5p (miR-501) was overexpressed in doxorubicin-resistant gastric cancer (GC) SGC7901/ADR cell-secreted exosomes (ADR Exo) than that in SGC7901 cell-secreted exosomes (7901 Exo). ADR Exo was internalized by SGC7901, and a Cy3-miR-501 mimic was transferred from SGC7901/ADR to SGC7901 via exosomes. ADR Exo conferred doxorubicin resistance, proliferation, migration and invasion abilities to negative control miRNA inhibitor-expressing GC cells, whereas it inhibited apoptosis. MiR-501 knockdown or BH3-like motif-containing protein, cell death inducer (BLID) overexpression could reverse the effects of ADR Exo on recipient cells. SGC7901 cells cocultured with SGC7901/ADR prior to treatment with GW4869 or transfection of a miR-501 inhibitor were sensitive to doxorubicin and exhibited attenuated proliferation, migration and invasion and increased apoptosis. The intratumoral injection of ADR Exo into negative control miRNA inhibitor-expressing SGC7901 cells induced rapid subcutaneous tumor growth and resistance to doxorubicin compared to that of miR-501 knockdown or BLID-overexpressing cells. This effect is possibly achieved by exosomal miR-501-induced downregulation of BLID, subsequent inactivation of caspase-9/-3 and phosphorylation of Akt. Exosomal miR-501 might be a therapeutic target for GC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canlet.2019.05.035

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 113

Metadata

Authors
Liu, X., Lu, Y., Xu, Y., Hou, S., Huang, J., Wang, B., Zhao, J., Xia, S., Fan, S., Yu, X., Du, Y., Hou, L., Li, Z., Ding, Z., An, S., Huang, B., Li, L., Tang, J., Ju, J., Guan, H., & Song, B.
Venue
Cancer Letters
Publisher
Elsevier BV
Published
2019-09
Volume
459
Pages
122-134
ISSN
0304-3835 (ISSN-L)
OpenAlex
W2948726665
Cited by
113
References
7
FWCI
5.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. https://app.cochat.ai/papers/10.1016/j.canlet.2019.05.035
The paper
Liu, X., Lu, Y., Xu, Y., Hou, S., Huang, J., Wang, B., Zhao, J., Xia, S., Fan, S., Yu, X., Du, Y., Hou, L., Li, Z., Ding, Z., An, S., Huang, B., Li, L., Tang, J., Ju, J., . . . Song, B. (2019). Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2019.05.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.